{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2022:BQBG7PUS2MJXPVPOULDM3LISHZ","short_pith_number":"pith:BQBG7PUS","schema_version":"1.0","canonical_sha256":"0c026fbe92d31377d5eea2c6cdad123e6098142a5dd9f40378daf8ab0e9b2ed9","source":{"kind":"arxiv","id":"2203.06830","version":1},"attestation_state":"computed","paper":{"title":"A Bayesian Precision Response-adaptive Phase II Clinical Trial Design for Radiotherapies with Competing Risk Survival Outcomes","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.AP","authors_text":"Hao Liu, Ick Hoon Jin, Jina Park, Wenjing Hu, Yong Zang","submitted_at":"2022-03-14T02:57:28Z","abstract_excerpt":"Many phase II clinical trials have used survival outcomes as the primary endpoints in recent decades. Suppose the radiotherapy is evaluated in a phase II trial using survival outcomes. In that case, the competing risk issue often arises because the time to disease progression can be censored by the time to normal tissue complications, and vice versa. Besides, much literature has examined that patients receiving the same radiotherapy dose may yield distinct responses due to their heterogeneous radiation susceptibility statuses. Therefore, the \"one-dose-fit-all\" strategy often fails, and it is m"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2203.06830","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2022-03-14T02:57:28Z","cross_cats_sorted":[],"title_canon_sha256":"71c84680f48d07ede640367a9dadfc4fdce2c3dd87dd90c735af2a6f75ee4c8d","abstract_canon_sha256":"3d51b71421ec000e96fd1dabe5b43c79a1172dd4bb76edf88c26e63aa170accd"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T04:04:56.179620Z","signature_b64":"HyNWT82jwnWBPZMJIINwESD5jHq7IqQQFthA21RPasBD3BII3P5RGFB4yVnR5buvLShGgGagWW+QN2LHoN0dBQ==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"0c026fbe92d31377d5eea2c6cdad123e6098142a5dd9f40378daf8ab0e9b2ed9","last_reissued_at":"2026-07-05T04:04:56.179112Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T04:04:56.179112Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"A Bayesian Precision Response-adaptive Phase II Clinical Trial Design for Radiotherapies with Competing Risk Survival Outcomes","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.AP","authors_text":"Hao Liu, Ick Hoon Jin, Jina Park, Wenjing Hu, Yong Zang","submitted_at":"2022-03-14T02:57:28Z","abstract_excerpt":"Many phase II clinical trials have used survival outcomes as the primary endpoints in recent decades. Suppose the radiotherapy is evaluated in a phase II trial using survival outcomes. In that case, the competing risk issue often arises because the time to disease progression can be censored by the time to normal tissue complications, and vice versa. Besides, much literature has examined that patients receiving the same radiotherapy dose may yield distinct responses due to their heterogeneous radiation susceptibility statuses. Therefore, the \"one-dose-fit-all\" strategy often fails, and it is m"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2203.06830","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2203.06830/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2203.06830","created_at":"2026-07-05T04:04:56.179172+00:00"},{"alias_kind":"arxiv_version","alias_value":"2203.06830v1","created_at":"2026-07-05T04:04:56.179172+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2203.06830","created_at":"2026-07-05T04:04:56.179172+00:00"},{"alias_kind":"pith_short_12","alias_value":"BQBG7PUS2MJX","created_at":"2026-07-05T04:04:56.179172+00:00"},{"alias_kind":"pith_short_16","alias_value":"BQBG7PUS2MJXPVPO","created_at":"2026-07-05T04:04:56.179172+00:00"},{"alias_kind":"pith_short_8","alias_value":"BQBG7PUS","created_at":"2026-07-05T04:04:56.179172+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ","json":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ.json","graph_json":"https://pith.science/api/pith-number/BQBG7PUS2MJXPVPOULDM3LISHZ/graph.json","events_json":"https://pith.science/api/pith-number/BQBG7PUS2MJXPVPOULDM3LISHZ/events.json","paper":"https://pith.science/paper/BQBG7PUS"},"agent_actions":{"view_html":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ","download_json":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ.json","view_paper":"https://pith.science/paper/BQBG7PUS","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2203.06830&json=true","fetch_graph":"https://pith.science/api/pith-number/BQBG7PUS2MJXPVPOULDM3LISHZ/graph.json","fetch_events":"https://pith.science/api/pith-number/BQBG7PUS2MJXPVPOULDM3LISHZ/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ/action/timestamp_anchor","attest_storage":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ/action/storage_attestation","attest_author":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ/action/author_attestation","sign_citation":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ/action/citation_signature","submit_replication":"https://pith.science/pith/BQBG7PUS2MJXPVPOULDM3LISHZ/action/replication_record"}},"created_at":"2026-07-05T04:04:56.179172+00:00","updated_at":"2026-07-05T04:04:56.179172+00:00"}